doi: 10.1111/j.1365-2141.1992.tb08208.x.
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation
Affiliations
- PMID: 1322690
- DOI: 10.1111/j.1365-2141.1992.tb08208.x
Item in Clipboard
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation
Br J Haematol.
1992 Jun.
Abstract
An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10(-12) M to 5 x 10(-14) M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.
Similar articles
-
Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.Lancet. 1992 May 16;339(8803):1195-6. doi: 10.1016/0140-6736(92)91135-u. Lancet. 1992. PMID: 1349939
-
Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.Br J Haematol. 1996 Mar;92(4):872-9. doi: 10.1046/j.1365-2141.1995.404942.x. Br J Haematol. 1996. PMID: 8616080
-
Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.Blood. 1995 Apr 15;85(8):2139-46. Blood. 1995. PMID: 7718885
-
Saporin immunotoxins.Curr Top Microbiol Immunol. 1998;234:57-61. doi: 10.1007/978-3-642-72153-3_4. Curr Top Microbiol Immunol. 1998. PMID: 9670612 Review. No abstract available.
-
Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.Methods Mol Biol. 2001;166:177-92. doi: 10.1385/1-59259-114-0:177. Methods Mol Biol. 2001. PMID: 11217367 Review. No abstract available.
Cited by
-
Saporin-S6: a useful tool in cancer therapy.Toxins (Basel). 2013 Oct 7;5(10):1698-722. doi: 10.3390/toxins5101698. Toxins (Basel). 2013. PMID: 24105401 Free PMC article. Review.
-
Hodgkin's lymphoma: the pathologist's viewpoint.J Clin Pathol. 2002 Mar;55(3):162-76. doi: 10.1136/jcp.55.3.162. J Clin Pathol. 2002. PMID: 11896065 Free PMC article. Review.
-
Pathobiology of anaplastic large cell lymphoma.Adv Hematol. 2010;2010:345053. doi: 10.1155/2010/345053. Epub 2011 Feb 6. Adv Hematol. 2010. PMID: 21331150 Free PMC article.
-
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.Blood Cancer J. 2017 Sep 8;7(9):e603. doi: 10.1038/bcj.2017.85. Blood Cancer J. 2017. PMID: 28885612 Free PMC article. Review.
-
Plant-Derived Type I Ribosome Inactivating Protein-Based Targeted Toxins: A Review of the Clinical Experience.Toxins (Basel). 2022 Aug 18;14(8):563. doi: 10.3390/toxins14080563. Toxins (Basel). 2022. PMID: 36006226 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
